Creatine Monohydrate vs GLP-1 for Energy: Which Is Better?
When it comes to enhancing energy levels and exercise performance, two compounds have emerged with solid evidence: creatine monohydrate, an inexpensive supplement that's been studied for decades, and GLP-1 receptor agonists, a newer class of peptide medications gaining attention for metabolic effects. Both demonstrate Tier 4 evidence for energy-related benefits, but they work through fundamentally different mechanisms and serve different populations. This article compares them directly for the specific goal of improving energy.
Quick Comparison Table
| Attribute | Creatine Monohydrate | GLP-1 Receptor Agonists |
|---|---|---|
| Type | Supplement | Peptide/Medication |
| Route | Oral | Injection |
| Dosing | 3–5g daily | 100–300 mcg daily/twice daily |
| Energy Evidence Tier | Tier 4 | Tier 4 |
| Primary Energy Mechanism | ATP regeneration via phosphocreatine system | Increased metabolic rate & mitochondrial function |
| Best For | High-intensity, short-duration exercise | Resting metabolic rate & overall energy expenditure |
| Cost/Month | $8–$25 | $40–$120 |
| Safety Profile | Excellent in healthy individuals | Well-established; prescription-only |
| Side Effects | Water retention, bloating, mild nausea | Nausea, vomiting, GI effects |
| Lean Mass Effect | Increases lean mass (+0.82 kg) | Decreases lean mass (−0.86 kg) |
Creatine Monohydrate for Energy
How It Works
Creatine monohydrate enhances energy by directly supporting the phosphocreatine energy system, the body's most rapid ATP-regeneration pathway. When muscles work at maximum intensity, they deplete ATP within seconds. Creatine donates a phosphate group to ADP, rapidly regenerating ATP and sustaining high-intensity effort for longer durations.
Supplementation increases total intramuscular creatine and phosphocreatine stores by 10–40%, significantly expanding the muscle's capacity for repeated maximal efforts. This mechanism makes creatine particularly suited for activities like weightlifting, sprinting, and other explosive movements.
Evidence for Energy
The evidence supporting creatine for energy is robust and consistent:
Muscle Creatine Loading: A foundational study demonstrated that creatine loading—20 g/day for 6 days—increased muscle total creatine concentration by approximately 20% within 6 days (n=31, human RCT). These elevated levels were then maintained with a maintenance dose of just 2 g/day, showing both the efficiency and sustainability of supplementation.
Power Output in Athletes: In elite youth soccer players, just 14 days of low-dose creatine supplementation (0.03 g·kg·day⁻¹) significantly increased peak power output (PPO) and mean power output (MPO) on the Wingate test (p≤0.05, n=19). The Wingate test is a gold-standard measure of anaerobic power, making this a clinically meaningful finding.
Repeated Sprint Performance: Creatine supplementation improved mean power output during repeated sprints by 4.5% and reduced speed decline within sprints by 16.2% (p=0.003–0.005, n=16, human RCT). This is particularly relevant for sports involving multiple high-intensity efforts separated by brief recovery periods.
Why It Works for Energy
The phosphocreatine system is the dominant energy source for exercises lasting 0–30 seconds. By increasing creatine availability, supplementation extends the body's ability to sustain high power output during this critical window. The effect is most pronounced in individuals performing repeated bouts of maximal effort with short recovery periods—the exact scenario that depletes phosphocreatine stores fastest.
GLP-1 Receptor Agonists for Energy
How It Works
GLP-1 receptor agonists enhance energy through a different pathway: increasing overall metabolic rate and improving mitochondrial function. These peptides bind to GLP-1 receptors, activating signaling cascades that elevate intracellular cAMP and trigger metabolic adaptations.
Unlike creatine, which specifically enhances ATP regeneration during high-intensity exercise, GLP-1 agonists improve the cellular machinery responsible for continuous ATP production. This results in improved resting energy expenditure, better mitochondrial efficiency, and enhanced oxygen utilization at the cellular level.
Evidence for Energy
24-Hour Energy Expenditure: A controlled trial in humans (n=49, RCT) showed that liraglutide, a GLP-1 agonist, increased 24-hour energy expenditure and improved glycemic control. The same participants showed reduced fasting glucose by 0.5–0.6 mmol/L compared to placebo (P<0.0001) after just 5 weeks of treatment.
Longitudinal Energy Expenditure: A longitudinal study tracking patients over 1 year found that both exenatide and liraglutide increased energy expenditure in obese individuals with type 2 diabetes. The sustained effect over an extended period suggests that the metabolic benefits are durable rather than transient.
Mitochondrial Function: While animal studies cannot be directly extrapolated to humans, semaglutide in db/db mice increased ATP production via elevated basal respiration, maximum respiration, and spare respiration capacity. It also improved mitochondrial morphology and promoted AMPK-dependent mitophagy—the cellular recycling of mitochondria. These mechanistic findings suggest that the energy-enhancing effects have a genuine biochemical basis.
Why It Works for Energy
GLP-1 agonists work by optimizing the cellular infrastructure for energy production. They enhance mitochondrial density and function, improve insulin sensitivity (allowing more efficient glucose utilization), and activate metabolic signaling pathways like AMPK. The net result is higher baseline energy expenditure and improved cellular energy status—particularly relevant for people with metabolic dysfunction, obesity, or type 2 diabetes.
Head-to-Head: Energy Performance
Both compounds achieve Tier 4 evidence for energy benefits, but their applications differ substantially.
Type of Energy Enhancement:
- Creatine: Maximizes peak power output and sustains high-intensity effort for 6–30 seconds. Its effect is most visible in tasks requiring maximal strength or explosive power.
- GLP-1: Increases resting metabolic rate and mitochondrial ATP production. Its benefit is most visible as improved endurance, sustained energy throughout the day, and better metabolic flexibility.
Study Population:
- Creatine: Evidence comes primarily from athletes and healthy individuals. Elite soccer players, weightlifters, and sprinters all show clear benefits.
- GLP-1: Evidence comes primarily from individuals with obesity or type 2 diabetes. The energy-enhancing effect is most apparent when baseline metabolic function is compromised.
Magnitude of Effect:
- Creatine: 4.5% improvement in repeated sprint power output is clinically meaningful and translates to measurable performance gains in competitive settings.
- GLP-1: Energy expenditure increases are modest in absolute terms but sustained over 24 hours, accumulating to meaningful weight loss and metabolic improvements over time.
Speed of Effect:
- Creatine: Loading effects appear within 6 days; steady-state improvements are evident within 14 days.
- GLP-1: Benefits emerge over 3–5 weeks and continue to improve over months of consistent use.